Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaglutide + treatment as usual
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Peptides, Small Molecules
- Administration
- Oral
01
Overview
Semaglutide + TAU refers to the adjunctive use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide alongside a patient's existing antipsychotic medication regimen, referred to in clinical trials as 'Treatment As Usual' (TAU). This specific combination is being evaluated in the ESCaMS trial (Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome), led by the All India Institute of Medical Sciences, Bhubaneswar. The intervention involves adding oral semaglutide (titrated to 3 mg once daily) to ongoing second-generation antipsychotic therapy to improve the cardiometabolic profile, reduce 10-year cardiovascular risk (QRISK3), and manage weight gain and insulin resistance associated with antipsychotic use. Semaglutide works by mimicking the GLP-1 hormone to regulate blood sugar and appetite, while the antipsychotic component typically manages psychiatric symptoms through dopamine and serotonin receptor antagonism.
- Other names
- semaglutide + tauSemaglutide + Treatment As Usual
02
Targets
Beyond the preview
Go deeper on semaglutide + treatment as usual.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaglutide + treatment as usual.